Governance
Investors
About us
Profile
Management
Board
Scientific Advisory Board
Our Science
Strategy
Enabling Technologies
Product Classes
Pipeline
Pipeline
Nidlegy
TM
Fibromun
Darleukin
Dodekin
Dekavil
Onco IX
OncoFAP Radio Conjugates
Tripokin
Press Releases & Events
Work with us
Careers
Partnering
About us
Profile
Management
Board
Scientific Advisory Board
Our Science
Strategy
Enabling Technologies
Product Classes
Pipeline
Pipeline
Nidlegy
TM
Fibromun
Darleukin
Dekavil
Dodekin
Onco IX
OncoFAP Radio Conjugates
Tripokin
Press Releases & Events
Work with us
Careers
Partnering
Investors
Investor Relations
Shareholding
IPO
Press Releases
Financial Statements
Financial Calendar
Internal Dealing
Buyback
Analyst Coverage
Webinars
IR Contacts
Governance
Board of Directors
Board of Statutory Auditors
Documents & Procedures
Shareholders’ Meetings
Codice etico e Modello 231
Sustainability (ESG)
Home
$
Governance
$
By-laws
By-laws
Board of Directors
Board of Statutory Auditors
Documents & Procedures
By-laws
Shareholders’ Meetings
Incentive Plans
Codice etico e Modello 231
Sustainability (ESG)
Statuto in vigore dal 18 maggio 2023
Statuto in vigore dal 18 maggio 2023 – mark up
Statuto dal 21 giugno 2021
Statuto dal 3 marzo 2021
